{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:07:00Z","timestamp":1792980420666,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Evidence suggests that opioid prescribing was reduced nationally following the 2016 release of the Guideline for Prescribing Opioids for Chronic Pain by the US Centers for Diseases Control and Prevention (CDC). State-to-state variability in postguideline changes has not been quantified and could point to further avenues for reducing opioid-related harms.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate state-level changes in opioid dispensing following the 2016 CDC Guideline release and explore state-to-state heterogeneity in those changes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study included information on opioid prescriptions for US individuals between 2012 and 2018 from an administrative database. Serial cross-sections of monthly opioid dispensing trajectories in each US state and the District of Columbia were analyzed using segmented regression to characterize preguideline dispensing trajectories and to estimate how those trajectories changed following the 2016 guideline release. Data were analyzed January to March 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n The March 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Four measures of opioid dispensing: opioid dispensing rate per 100\u202f000 persons, long-acting opioid dispensing rate per 100\u202f000 persons, high-dose (90 or more morphine milligram equivalents [MME] per day) dispensing rate per 100\u202f000 persons, and average per capita MME. All measures were calculated monthly, from January 2012 through December 2018.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Data from approximately 58\u202f900 retail pharmacies were included in analysis, representing approximately 92% of US retail prescriptions. The overall monthly dispensing rate in the US in early 2012 was approximately 7000 per 100\u202f000 population. Following the 2016 guideline release, the already-decreasing slope accelerated nationally for the overall dispensing rate (preguideline slope, \u221223.19; postguideline slope, \u221248.97; change in slope, 25.97 [95% CI, 18.67-32.95]), long-acting dispensing rate (preguideline slope, \u22121.03; postguideline slope, \u22125.94; change in slope, 4.90 [95% CI, 4.26-5.55]), high-dose dispensing (preguideline slope, \u22123.52; postguideline slope, \u22127.63; change in slope, 4.11 [95% CI, 3.49-4.73]), and per-capita MME (preguideline slope, \u22120.22; postguideline slope, \u22120.58; change in slope, 0.36 [95% CI, 0.30-0.42]). For all outcomes, nearly all states showed analogous acceleration of an already-decreasing slope, but there was substantial state-to-state heterogeneity. Slope changes (preguideline\u2009\u2212\u2009postguideline slope) ranged from 9.15 (Massachusetts) to 74.75 (Mississippi) for overall dispensing, 1.88 (Rhode Island) to 13.41 (Maine) for long-acting dispensing, 0.71 (District of Columbia) to 13.68 (Maine) for high-dose dispensing, and 0.06 (Hawaii) to 0.91 (Arkansas) for per capita MME.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The 2016 CDC Guideline release was associated with broad reductions in prescription opioid dispensing, and those changes showed substantial geographic variability. Determining the factors associated with these state-level differences may inform further improvements to ensure safe prescribing practices.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.32507","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:01:08Z","timestamp":1694430068000},"page":"e2332507","source":"Crossref","is-referenced-by-count":29,"title":["State-to-State Variation in Opioid Dispensing Changes Following the Release of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain"],"prefix":"10.1001","volume":"6","author":[{"given":"Xiru","family":"Lyu","sequence":"first","affiliation":[{"name":"Injury Prevention Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gery P.","family":"Guy","sequence":"additional","affiliation":[{"name":"Division of Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant T.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Division of Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Losby","sequence":"additional","affiliation":[{"name":"Division of Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S. B.","family":"Bohnert","sequence":"additional","affiliation":[{"name":"Injury Prevention Center, University of Michigan, Ann Arbor"},{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor"},{"name":"Department of Psychiatry, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Goldstick","sequence":"additional","affiliation":[{"name":"Injury Prevention Center, University of Michigan, Ann Arbor"},{"name":"Department of Emergency Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"1","key":"zoi230940r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"16","key":"zoi230940r2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJMp1515917","article-title":"Reducing the risks of relief\u2013the CDC opioid-prescribing guideline.","volume":"374","author":"Frieden","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi230940r3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States, 2016.","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"zoi230940r4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 opioid guideline.","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi230940r5","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1377\/hlthaff.2021.00135","article-title":"CDC guideline for opioid prescribing associated with reduced dispensing to certain patients with chronic pain.","volume":"40","author":"Townsend","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"zoi230940r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16860","article-title":"Changes in initial opioid prescribing practices after the 2016 release of the CDC Guideline for Prescribing Opioids for Chronic Pain.","volume":"4","author":"Goldstick","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi230940r7","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/pm\/pnac068","article-title":"Changes in opioid dispensing by medical specialties after the release of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.","volume":"23","author":"Salvatore","year":"2022","journal-title":"Pain Med"},{"issue":"11","key":"zoi230940r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16271","article-title":"Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008-2017.","volume":"2","author":"Fenton","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi230940r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.11997","article-title":"Unintended consequences from the 2016 US Centers for Disease Control and Prevention Guideline for Prescribing Opioids\u2014accelerating change in postoperative prescribing.","volume":"4","author":"Bicket","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"24","key":"zoi230940r10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing.","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230940r11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMp2211040","article-title":"Prescribing opioids for pain\u2014the new CDC clinical practice guideline.","volume":"387","author":"Dowell","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi230940r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain\u2014United States, 2022.","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"zoi230940r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16475","article-title":"Patterns in nonopioid pain medication prescribing after the release of the 2016 Guideline for Prescribing Opioids for Chronic Pain.","volume":"5","author":"Goldstick","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi230940r15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019.","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"403","key":"zoi230940r16","first-page":"1","article-title":"Urban-rural differences in drug overdose death rates, 1999-2019.","author":"Hedegaard","year":"2021","journal-title":"NCHS Data Brief"},{"issue":"10","key":"zoi230940r17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jpain.2012.07.007","article-title":"Geographic variation in opioid prescribing in the U.S.","volume":"13","author":"McDonald","year":"2012","journal-title":"J Pain"},{"issue":"3","key":"zoi230940r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0665","article-title":"Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017.","volume":"2","author":"Schieber","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi230940r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder.","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi230940r21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2018.6989","article-title":"County-level opioid prescribing in the United States, 2015 and 2017.","volume":"179","author":"Guy","year":"2019","journal-title":"JAMA Intern Med"},{"key":"zoi230940r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103686","article-title":"Shifting of opioid prescription rate reporting impacts both rural and urban counties.","volume":"104","author":"Hudnall","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi230940r24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"zoi230940r25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/milq.v98.1","article-title":"The association of state opioid misuse prevention policies with patient- and provider-related outcomes: a scoping review.","volume":"98","author":"Mauri","year":"2020","journal-title":"Milbank Q"},{"issue":"2","key":"zoi230940r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36687","article-title":"Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007-2018.","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi230940r14","unstructured":"US Centers for Disease Control and Prevention (CDC). Drug Overdose Mortality by State. National Center for Health Statistics. Reviewed March 1, 2022. Accessed January 6, 2023. https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm"},{"key":"zoi230940r20","unstructured":"IQVIA. Prescription Information, 2018-2022. IQVIA website. Accessed January 6, 2023. https:\/\/www.iqvia.com\/locations\/united-states\/solutions\/life-sciences\/information-solutions\/essential-information\/prescription-information"},{"key":"zoi230940r23","unstructured":"United States Census Bureau. American Community Survey 1-Year Data (2005-2021). Updated September 15, 2022. Accessed January 6, 2023. https:\/\/www.census.gov\/data\/developers\/data-sets\/acs-1year.html"},{"key":"zoi230940r26","unstructured":"Federation of State Medical Boards. Prescription Drug Monitoring Programs. Updated January 2023. Accessed January 6, 2023. https:\/\/www.fsmb.org\/siteassets\/advocacy\/key-issues\/prescription-drug-monitoring-programs-by-state.pdf"},{"key":"zoi230940r27","unstructured":"US Centers for Disease Control and Prevention (CDC). Multiple Cause of Death 1999-2020. Last reviewed May 12, 2023. Accessed January 6, 2023. https:\/\/wonder.cdc.gov\/wonder\/help\/mcd.html"},{"key":"zoi230940r29","unstructured":"US Centers for Disease Control and Prevention (CDC). Summary of the 2022 Clinical Practice Guideline for Prescribing Opioids for Pain. Last reviewed November 3, 2022. Accessed July 14, 2023. https:\/\/www.cdc.gov\/opioids\/patients\/guideline.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809155\/lyu_2023_oi_230940_1693416418.83852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:01:13Z","timestamp":1694430073000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.32507","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}